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Objective: To evaluate the pathological characteristics of peritumoral capsule (PC) and the prognostic effect of capsule penetration on
tumor recurrence in patients treated with tumor enucleation for clinically intracapsular renal cell carcinomas (RCCs).
Methods and materials: PC status was analyzed in 304 consecutive patients with single intracapsular RCC. Degree and side of capsule
penetration if present were evaluated. Mean (median, range) follow-up was 49 months (46, 25–69). Local recurrence rate, progression-free
survival (PFS), and cancer-specific survival were the main outcomes. Statistical analyses included the Kaplan-Meier method, log-rank test,
and univariate and multivariate Cox regression models.
Results: Overall, 51% of RCCs had intact PC and free from neoplastic invasion (PC), 34.9% had capsular penetration on the
parenchymal side (PCK), and 14.1% had tumor invasion on the perirenal fat tissue side (PCF). None of the patients had positive surgical
margins. The 5-year PFS rates for tumors PC, PCK, and PCF were 97.5%, 96.7%, and 77.1%, respectively (Po 0.0001).
The multivariate Cox model showed PCF to be the sole significant independent predictor of PFS, whereas patients who had PCK did not
present a significant increased risk in developing recurrence.
Conclusions: Tumor enucleation is an oncologically safe nephron-sparing surgery technique. PCF is a significant and independent
predictor of tumor recurrence in patients with clinically intracapsular RCCs scheduled for nephron-sparing surgery. PCK does not predict the
risk of recurrence. r 2014 Elsevier Inc. All rights reserved.
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With the widespread use of modern imaging techniques,
a growing number of small renal tumors are being
diagnosed and treated by nephron-sparing surgery (NSS).
The recent European Association of Urology guidelines
expanded its indication for solitary renal cell carcinoma
(RCC) up to a diameter of 7 cm, whenever technically
feasible. A minimal tumor-free surgical margin appears
appropriate to avoid the risk of local recurrence, thusmatter r 2014 Elsevier Inc. All rights reserved.
.urolonc.2013.07.018
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amine@libero.it, andrea.minervini@unifi.itsupporting the possible use of the tumor enucleation (TE),
which is a nephron-sparing procedure with oncological
effectiveness supported by numerous papers (Level of
Evidence 2b) [1–8]. Over the past years, this technique
has received a wider consensus as an alternative to standard
partial nephrectomy for T1 RCC and has been adopted in
several centers [8].
Overall, many large series with single sporadic RCC
treated conservatively by either standard partial nephrectomy
or TE reported favorable survival and recurrence rates, but
tumor progression may occur in some cases [2,4–7,9–12].
This evidence has led to identifying clinical and patho-
logical parameters as predictors of disease progression.
The available published evidence indicates that the TNM
A. Minervini et al. / Urologic Oncology: Seminars and Original Investigations 32 (2014) 50.e15–50.e2250.e16staging system, tumor size, histological subtype, Fuhrman
grade, and indications for NSS (elective vs. imperative)
are significant predictors of cancer-specific survival (CSS)
[12–15].
The TNM staging system uses tumor size as a single
prognostic factor for clinically intracapsular RCC. How-
ever, tumor size may be considered a scarcely reliable
prognostic factor in distinguishing tumors with different
biological behavior, and other pathological parameters
could bring a significant improvement in the prognostic
assessment of RCCs.
Most renal tumors amenable for conservative surgery
tend to compress the normal parenchyma and have a
continuous fibrous capsule around it [3,16–19]. We
hypothesized that peritumoral fibrous capsule penetration
on either the parenchymal side or the perinephric adipose
tissue side might provide the first pathological evidence of
tumor cells' capacity to infiltrate and invade surrounding
tissue, which could eventually increase the risk of tumor
recurrence, thus emerging as a useful and significant
prognostic factor in patients with clinically intracapsular
RCC [3,16–19]. The prognostic implication of renal cap-
sular involvement in patients with RCC is quite well
assessed [18–25]. However, until now there is no knowl-
edge about the correlation of the individual oncological
course with extend and side of infiltration of the tumor
capsule. The aim of the present study is to analyze
prospectively the pathological characteristics, to examine
the side and degree of capsular penetration in patients with
single, sporadic, clinically intracapsular RCC, and to
evaluate the prognostic effect of capsule penetration on
local and systemic recurrence in a consecutive series of 304
patients treated by TE.2. Methods and materials
After institutional review board approval was obtained,
data were gathered prospectively from 451 consecutive
patients who underwent TE between January 2005 and June
2011. Patients with histologically confirmed benign tumors
(97 patients, 21.5%), patients with solitary kidney owing to
previous RCC treated by radical nephrectomy (19 patients,
4.2%), and those with multiple ipsilateral (22 patients,
4.9%) and synchronous bilateral RCCs (9 patient, 2%)
were excluded from the study, thus leaving 304 (67.4%)
consecutive patients treated with elective NSS (277 patients,
91.2%) or with imperative indication (27 patients, 8.8%).
The preoperative evaluation included abdominal ultraso-
nography and computed tomography (CT) with contrast
medium and a chest x-ray in all patients. None of the 304
patients had preoperative or intraoperative suspicion of
positive nodes. All patients were presumably free from
distant metastases before surgery (M0).
In all cases, TE was done according to our previously
described standard protocol, by blunt dissection with novisible rim of healthy tissue and always using the natural
cleavage plane between the tumor and normal parenchyma
[3,5]. The tumor specimen was oriented in the operating
theater, positioning one suture at the deepest part of the
inner pole of the tumor and another, of a different color, at
the level where the tumor became exophytic.
After formalin fixation (10%), all specimens were step-
sectioned at 5-mm intervals, and the entire specimen was
analyzed by 2 dedicated uropathologists. Patients were
staged according to the 2009 American Joint Committee
on Cancer-Union International Centre le Cancer TNM
classification [26], and nuclear grading was assigned
according to criteria proposed by Fuhrman et al. [27]. The
histopathology was reviewed according to the 2004 WHO
classification [28]. The existence, integrity, width, and
depth of cancer penetration of peritumoral capsule (PC), if
present, were evaluated and recorded. PC thickness was
measured at the inner and at the outer pole of the specimen.
PC classification is reported in the Panel (Fig. 1).
The follow-up schedule included blood chemistries and
chest x-rays in association with either ultrasound or CT of
the abdomen every 3 to 4 months for the first year after
surgery, every 6 months from postoperative years 2 to 5,
and annually thereafter. Bone scintigraphy and chest CT
were used only when there was clinical suspicion.
The unpaired student t test and χ2 test were used to
evaluate the possible statistical correlation between the
clinical and pathological variables and the risk of PC
invasion. Local recurrence rate, progression-free survival
(PFS), and CSS were the main outcomes of this study. The
probability of survival was estimated by the Kaplan-Meier
method, with the log-rank test used to estimate differences
among levels of the analyzed variables. Univariate and
multivariate Cox regression models addressed time to PFS.
TNM stage was not included in the multivariable model to
avoid the risk to overfit the model because of colinearity
with PC status (perirenal fat tissue side [PCFþþ] equal to
focal pT3a). Statistical significance was set at Pr 0.05.
Analyses were conducted using all events in Stat View
5.0.1 (SAS Institute Inc., Cary, NC).3. Results
Preoperative characteristics, clinical presentation, and
pathological data of the 304 patients included in the study
are reported in Table 1.
All RCCs were surrounded by a continuous, not
fenestrated fibrous capsule constituted by dense connective
fibrous tissue. Mean PC thickness at the inner pole of the
tumor (standard deviation, median, and range) was 412 μm
(250, 350, 20–1,511). Mean PC thickness at the outer pole
of the tumor (standard deviation, median, and range) was
385 μm (253, 358, and 20–1,770, respectively). Of the
304 RCCs, in 155 (51%), the peritumoral capsule was
intact and free from neoplastic invasion (PC), whereas in
Fig. 1. (A) PC (PC intact and free from neoplastic penetration); (B and C) PCKþ (PC with signs of neoplastic penetration on parenchymal kidney side); (D)
PCKþþ(PC with complete neoplastic penetration on parenchymal kidney side); (E) PCFþ (PC with signs of neoplastic penetration on the perirenal adipose
tissue side); (F and G) PCFþþ(PC with complete neoplastic penetration on the adipose tissue side, focal microscopic pT3a). K ¼ kidney; PC ¼ peritumoral
capsule; T ¼ tumor; F ¼ perirenal fat. Red arrow indicates neoplastic penetration. (Color version of figure is available online.)
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layers. The capsular features according to the side and
degree of neoplastic penetration are reported in Fig. 1 and
Table 2. The pathologists applied ink to the enucleated
tumor in all cases, but in none the ink touched the surface
of the tumor.
Correlation analyses showed a statistically significant
association of capsular invasion with symptoms at presen-
tation, TNM stage, and tumor greatest dimension, whereas
age, imperative indications for surgery, histological sub-
type, Fuhrman grade, and PC thickness were not.
Mean (median, range, and interquartile range) follow-up
was 49 months (52, 12–96, and 16–88, respectively).
During follow-up, 13 patients had progressive disease
(4.3%). Clinicopathological characteristics and outcomes
of patients who had disease progression are reported in
Table 3.
The 5-year overall survival was 93.8%. The 3- and
5-year CSS rates were 98.2%. The 3- and 5-year PFS rates
were 95.3% and 94.8%, respectively. The crude recurrence rateaccording to PC status was 1.9% for PC, 1.3% for PCKþ,
6.4% for PCKþþ, 11.1% for PCFþ, and 20% for PCFþþ. The
5-year PFS rate for RCC according to PC status was as
follows: PC, 97.5%; PCKþ, 98.2%; PCKþþ, 92.8%; PCFþ,
82.6%; and PCFþþ, 74% (Po 0.0001; PC vs. PCKþ, P ¼
0.68; PC vs. PCKþþ, P ¼ 0.1247; PC vs. PCFþ,
Po0.0113; and PC vs. PCFþþ, Po 0.0001; Fig. 2).
No statistically significant difference in the risk of
progression was observed between PCKþ and PCKþþ(P ¼
0.106) and between PCFþ and PCFþþ(P ¼ 0.6). Therefore,
we defined 3 prognostic classes, i.e. PC, PCK (þ andþþ),
and PCF (þ andþþ). The 5-year PFS rates for tumors PC,
PCK, and PCF were 97.5%, 96.7%, and 77.1%, respectively
(Po 0.0001). At univariate analysis, factors associated with
worse PFS were capsular penetration on the perirenal tissue
side, imperative indications for conservative surgery, tumor
greatest dimension, and higher tumor stage (Table 4). The
TNM stage was not included in the multivariable model
because of colinearity with PC status, and multivariable Cox
regression model showed PCF to be the sole significant
Table 1
Patients' characteristics, clinical presentation, and pathological features of
304 renal cell carcinomas (RCCs) treated with NSS
Variables n (%) or mean
(SD; range; IQR)
Mean age 63 (13; 22–85; 56–73)
Gender
Male 192 (63%)
Female 112 (37%)
Tumor side
Right 164 (53.9%)
Left 140 (46.1%)
No. Symptomatic at presentation 30 (9.8%)
Indications for NSS
Elective 277 (91.2%)
Imperative 27 (8.8%)
Tumor location
Upper pole 79 (26%)
Mid kidney 136 (44.7%)
Lowe pole 71 (23.3%)
Perihilar 18 (6%)
Mean (SD; range) clinical tumor size (cm) 3.4 (1.4; 1.2–10)
Mean (SD; range) pathological tumor size (cm) 3.4 (1.4, 1–12.5)
Tumor histotype
Clear cell RCC 209 (68.8%)
Papillary RCC 53 (17.5%)
Chromophobe RCC 39 (12.8%)
Others 3 (0.9%)
TNM 2009
pT1a 215 (70.7%)
pT1b 60 (19.8%)
pT2a 3 (0.9%)
pT2b 1 (0.3%)
pT3a 25 (8.2%)
Fuhrman grade
G1 42 (15.5%)
G2 201 (74.2%)
G3 27 (10%)
G4 1 (0.3%)
IQR ¼ interquartile range; SD ¼ standard deviation.
A. Minervini et al. / Urologic Oncology: Seminars and Original Investigations 32 (2014) 50.e15–50.e2250.e18independent predictor of PFS (Table 4). In particular,
patients with PCF had a 6-fold higher risk of disease
progression than patients with an intact capsule (confidence
interval [CI] 1.579–29.085; P ¼ 0.01) and a 5-fold higher
risk of disease progression than PCK (CI 1.244–21.220;
P ¼ 0.0237), whereas patients who had PCK did not
present a significant increased risk in developing a relapseTable 2
PC features of 304 renal cell carcinomas (RCCs) from patients who underwent t
PC status Number of cases (%) % Clear cell (%)
PC 155 51 110 (52.6)
PCK 106 34.9 71 (34)
PCKþ 75 24.7 54 (25.9)
PCKþþ 31 10.2 17 (8.1)
PCF 43 14.1 28 (13.4)
PCFþ 18 5.9 11 (5.3)
PCFþþ 25 8.2 17 (8.1)
Total 304 100 209in comparison with PC (CI 0.262–6.649; P ¼ 0.7371;
Table 4).
Then, we created a subset of patients by eliminating
PCFþþand PCKþþwith the aim to confirm the prognostic
role of capsular invasion also in the subgroups of tumors
with no tumor cells outside the peritumoral capsule.
At univariate Cox model, PCFþ was confirmed to be
significantly associated with a worse PFS (P ¼ 0.0421)
(Table 5).4. Discussion
The studies on the capsular characteristics and involve-
ment in RCCs were historically focused on the parenchymal
side of the tumor to evaluate the technical feasibility and
oncological safety of blunt TE, and a higher rate of PC
invasion in larger and less differentiated tumors was
reported [29]. More recently, Li et al. [18] prospectively
studied 82 kidneys with RCC with a mean tumor diameter
of 3.4 cm and showed a capsular penetration on the kidney
side in 26.8% of cases, which was confirmed by us in a
previous study (26.6%) and was even higher in the present
consecutive series (34.9%) [3].
The evaluation of capsular involvement on the perirenal
tissue side is more recent with the aim to better stratify the
prognosis of patients with intracapsular tumors. These
studies on large retrospective series showed a great varia-
bility in PC invasion rate on the perirenal tissue side
(PCFþ) (7.2%–37.5%, Table 6) [20–25]. In our series of
RCC with a mean (range) tumor size of 3.4 cm (1–12.5),
PCFþ was present in 5.9% of RCCs, similar to the 7.2%
reported by Rouach and coworkers in a study of 305 RCCs
with a mean (range) tumor dimension of 3.5 (0.5–15) cm.
One possible explanation to this great variability is the
difference in mean tumor dimension but also in the reported
incidence of clear cell RCC, although ourselves and Klatte
et al. [23] did not find an association between tumor
histotype and PC invasion [3]. Another possible reason is
related to the different magnifying resolution possibly used
to define PC invasion between studies that eventually led us
to diagnose a higher rate of PCFþþ(8.2% of focal micro-
scopic pT3a), but unfortunately these data were not reported
in most of the studies on this topic [20–25]. Indeed, aumor enucleation
Papillary (%) Chromophobe (%) Others (%)
23 (43.4) 19 (48.7) 3 (100)
19 (35.8) 16 (41) 0
7 (13.2) 14 (35.9) 0
12 (22.6) 2 (5.1) 0
11 (20.8) 4 (10.3) 0
4 (7.6) 3 (7.7) 0
7 (13.2) 1 (2.6) 0
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exclude this bias from future studies.
Peritumoral capsule pathological analysis and its evalua-
tion as a prognostic factor are not new for pathologists.
Indeed, in other tumors, as in follicular thyroid neoplasm,
the penetration of fibrous capsule was analyzed and was
found to be associated with a malignant phenotype [30].
Also for RCCs, the presence of a capsular involvement
could represent the first pathological evidence of the
capacity achieved by tumor cells to infiltrate and invade
normal parenchyma and perirenal tissue, and might poten-
tially increase the risk of local and systemic recurrence, and
could eventually be used as a prognostic factor in patients
with clinically intracapsular RCC amenable for conservative
surgery. However, the prognostic effect of peritumoral
fibrous capsule penetration remains controversial [3,19–
25]. A few authors recently investigated the prognostic
implication of capsular involvement on the perinephric fat
side in patients treated with either radical nephrectomy or
NSS (Table 6) [20–25]. Overall, more than 2,000 patients
were evaluated, and the mean follow-up ranged between 40
and 86 months [20–25]. Two reports did not find PCFþ to
be a predictor of disease recurrence [24,25]. Possible
criticisms of these papers reside in their retrospective
nature, the long time frame of the studies, and the re-
evaluation of selected slides only, instead of the entire
specimen. On the contrary, most of these reports showed
PCFþ to have a significant effect on disease-free survival
[20–24]. In our series, we confirm the prognostic effect of
PCFþ at univariate analyses, and we did not observe a
statistically significant difference in the risk of progression
between PCFþ and PCFþþ, in agreement with Klatte et al.
[23] who reported PCFþ tumors having an identical
recurrence-free survival to those with PCFþþ. In our
analysis, we merged PCFþ and PCFþþand showed that
this neoplastic event (PCF) was the only independent
predictor of recurrence-free survival. In patients with
clinically intracapsular RCCs scheduled for NSS, capsular
invasion on the perinephric tissue side appears to be a
strong predictor of recurrence-free survival (Table 4). More-
over, our accurate pathological analysis allowed us to
conclude that RCCs suitable for NSS are surrounded by a
continuous, not fenestrated fibrous pseudocapsule and that
PCKþ and PCKþþdo not present a significant increased
risk of developing local and systemic recurrence in com-
parison with PC when TE is performed, and it clearly
represents a rationale to safely adopt this technique for the
excision of clinically intracapsular RCC. Peritumoral pseu-
docapsule can be penetrated irrespective of tumor size, with
a reported infiltration rate of 34.9% on the parenchymal
side, but the presence of a thin layer of parenchymal tissue
with signs of lymphoplasmocytic inflammation allows
for negative surgical margins, also if no efforts are made
to leave a rim of healthy kidney tissue around the neo-
plasm [3]. This thin rim of normal parenchymal tissue is
always present in case of neoplastic penetration of the
Fig. 2. Progression-free survival (PFS) probability according to PC status.
Five-year PFS was 97.5% in PC, 98.2% in PCKþ, 92.8% in PCKþþ,
PCFþ, 82.6% in PCFþ, and 74% in PCFþþ. (Color version of figure is
available online.)
Table 5
Univariable Cox regression analysis for prediction of progression-free
survival in the subgroup of tumors with no tumor cells outside the
peritumoral capsule (245 patients; PC, PCKþ, and PCFþ)
Parameter Univariable analysis
HR 95% CI P value
Pathological tumor size, continuous 1.156 0.740–1.805 0.5240
Pathological T stage 0.4347
T1a 1 Reference –
T1b 1.967 0.360–10.749 –
PC status 0.0421
PC 1 Reference –
PCKþ 1.569 0.163–15.103 0.6965
PCFþ 12.421 1.105–139.577 0.0412
HR ¼ hazard ratio.
A. Minervini et al. / Urologic Oncology: Seminars and Original Investigations 32 (2014) 50.e15–50.e2250.e20pseudocapsule into the kidney tissue (PCKþþ). Therefore, if
the surgeon follows the natural cleavage plane between
tumor pseudocapsule and kidney parenchyma by blunt
dissection, thus performing a TE, there is a limited risk of
positive surgical margins even with larger masses.Table 4
Univariable and multivariable Cox regression analyses for prediction of progress
Parameter Univariable analysis
HR 95% CI
Age, continuous 0.990 0.949–1.033
Symptoms at presentation
Absent 1 Reference
Present 2.030 0.448–9.198
Indication for surgery
Elective 1 Reference
Imperative 4.704 1.446–15.303
Pathological tumor size, continuous 1.333 1.084–1.638
Pathological T stage
T1a 1 Reference
T1b 2.064 0.493–8.641
T3a 9.531 2.756–32.959
Fuhrman nuclear grade
G1-2 1 Reference
G3-4 1.783 0.394–8.064
PC status
PC 1 Reference
PCK 1.438 0.290–7.125
PCF 10.095 2.601–39.180
HR ¼ hazard ratio.In daily pathology practice, addressing the peritumoral
capsule status is easy and straightforward without the need
for obtaining special stains or extra slides and without the
additional expense in time and cost, and according to the
results obtained by our study and by previous retrospective
series, we believe that this feature should be routinely
assessed during the specimen analysis [3,19].
Limitations of the present study include the relatively
few patients enrolled, which however exceeds that of most
peer articles, and the medium-term follow-up, as systemic
tumor recurrence after NSS has been reported to occur well
past the 49-month follow-up horizon. However, this is a
homogeneous series of patients, all had NSS performed by
TE, and 2 dedicated uropathologists thoroughly analyzed
the entire specimens and completed the pathological reports
in consensus with a precise pathological analysis. Furtherion-free survival in 304 patients after TE
Multivariable analysis
P value HR 95% CI P value
0.6434 – – –
0.3586 – – –
–
–
0.0101 0.2324
– 1 Reference –
– 2.224 0.599–8.256 –
0.0064 1.169 0.885–1.544 0.2701
0.0015 – – –
–
0.3211
0.0004
0.4523 – – –
–
–
0.0006 0.0133
– 1 Reference –
0.6566 1.319 0.262–6.649 0.7371
0.0008 6.777 1.579–29.085 0.0100
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A. Minervini et al. / Urologic Oncology: Seminars and Original Investigations 32 (2014) 50.e15–50.e22 50.e21advantage of this work is assessment based on a stand-
ardized prospective protocol of histopathological evaluation
of the specimens. However, even based on a standardized
protocol with 5 mm step-sections, some areas of the
peritumoral capsule remained unrated.
We acknowledge that a number of our pathological
findings on a limited number of patients have already
appeared in the literature [3,5]. However, this study
represents the first series where capsular involvement on
both the perinephric side and the parenchymal side was
evaluated from a prognostic perspective at a mean follow-
up of more than 4 years and reported not only the rate of
local recurrence but also systemic relapses.
Additional observation would be mandatory and could
eventually reinforce our results, and multicentric studies
should be conducted to strengthen the statistical power of
the study.5. Conclusions
Peritumoral capsule invasion is a frequent finding in
localized RCCs, which appears to occur at a higher rate on
the parenchymal side than on the perirenal tissue side in the
reported cases. A capsule penetration on the perirenal adipose
tissue side is a significant and independent predictor of tumor
recurrence, with a relative risk of disease progression nearly 6
times higher than an intact peritumoral capsule. For clinically
intracapsular tumors amenable for conservative surgery, the
accurate analysis of the capsular status at the perirenal tissue
side could overtake the TNM staging system for risk strat-
ification of disease recurrence. A capsule penetration on the
parenchymal side does not predict the risk of local and
systemic recurrence even if a TE is performed.
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